Sangamo Selects PTC and Lilly as Winning Bidders in $163.55M Asset Auction
SGMOQ has more than doubled off its 52-week low of $0.03.
Summary
Sangamo Therapeutics announced winning bidders in its bankruptcy asset auction: PTC Therapeutics for the Fabry disease program ($111M cash + up to $100M milestones) and Eli Lilly for platform technologies and prion disease program ($50M cash), totaling approximately $163.55 million in cash consideration at closing.
Key Events · M&A and Partnerships · SGMOQ
-
Winning Bidders Selected
PTC Therapeutics selected for Fabry disease program (ST-920) at $111M cash plus up to $100M in milestones; Eli Lilly selected for capsid delivery, zinc finger, MINT platforms, and prion disease program (ST-506) at $50M cash.
-
Total Cash Consideration
Approximately $163.55 million in cash at closing, including $2.55 million from tools and equipment sales to various bidders.
-
Milestone Structure
PTC deal includes up to $100 million in future milestones: $80 million upon FDA accelerated approval and $20 million upon traditional or full approval.
-
Closing Timeline
Lilly transaction expected to close on or about September 4, 2026; PTC transaction expected to close following HSR antitrust review. Sale hearings expected in Q3 2026.
Analysis · SGMOQ · Life Sciences
Sangamo Therapeutics, operating under Chapter 11 bankruptcy protection, has selected winning bidders for its key assets following a court-supervised auction. PTC Therapeutics will acquire the Fabry disease program for $111 million in cash plus up to $100 million in milestone payments, while Eli Lilly will acquire the capsid delivery, zinc finger, and MINT platforms along with the prion disease program for $50 million. Additional tools and equipment sales bring total cash consideration at closing to approximately $163.55 million. The transactions remain subject to bankruptcy court approval and regulatory clearances, with the Lilly deal expected to close around September 4, 2026, and the PTC deal following HSR review. For a company with a market cap of only $63.6 million, this asset sale represents a transformative liquidity event that will determine the ultimate recovery for stakeholders in the Chapter 11 case.
At the time of this filing, SGMOQ was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $63.6M. The 52-week trading range was $0.03 to $0.77. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.